Similar Effectiveness of Both Formulations of Tocilizumab (TCZ) in Patients with Rheumatoid Arthritis (RA) Switching from Intravenous (IV) to Subcutaneous (SC) at 6 Months in Real Life - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Arthritis & rheumatology Année : 2017

Similar Effectiveness of Both Formulations of Tocilizumab (TCZ) in Patients with Rheumatoid Arthritis (RA) Switching from Intravenous (IV) to Subcutaneous (SC) at 6 Months in Real Life

, (1, 2) , , (3) , (4) , (5) , (6) , (7) , , (8) , (9) , (10)
1
2
3
4
5
6
7
8
9
10
Fichier non déposé

Dates et versions

hal-03606091 , version 1 (11-03-2022)

Identifiants

  • HAL Id : hal-03606091 , version 1

Citer

Jean Darloy, Rene-Marc Flipo, Nicolas Segaud, Jean-Paul Eschard, Vincent Goeb, et al.. Similar Effectiveness of Both Formulations of Tocilizumab (TCZ) in Patients with Rheumatoid Arthritis (RA) Switching from Intravenous (IV) to Subcutaneous (SC) at 6 Months in Real Life. Arthritis & rheumatology, 2017, 69 (10). ⟨hal-03606091⟩
6 Consultations
0 Téléchargements

Partager

Gmail Facebook Twitter LinkedIn More